A Phase 2 interventional study of No Intervention and donanemab in Alzheimer Disease, Dementia and Brain Diseases, sponsored by Eli Lilly and Company. Completed at 27 sites in 2 countries. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing donanemab in Alzheimer Disease — 7 open to participants now, 10 under way, 6 of them phase 3. donanemab · Alzheimer Disease.
Among the 15 studies testing donanemab in Alzheimer Disease, this one is the 11th largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 5th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →7 of the 15 studies testing donanemab in Alzheimer Disease are open now, in 8 countries. Recruiting first, the newest first:
Banner Health · Sites in Colombia
Ages 25–65 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Japan, Puerto Rico
Ages 55+
Eli Lilly and Company · Sites in United States, Japan, Korea, Republic of and 1 more country
Ages 55–85
Eli Lilly and Company · Sites in China
Ages 55–80
Paul S. Aisen · Sites in United States
Ages 50–80
By country, each count listing its studies:
donanemab: first FDA approval 2024 (KISUNLA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 60 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2013; this study’s year is marked. 2 started in 2020.
This study's enrollment of 95 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 240 across the 15 interventional studies. Of the 5 that completed or were terminated, 5 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 4 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 48th largest by enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2020, is one of 23 in phase 2, and was the 78th registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
1 of the studies testing donanemab in Alzheimer Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05026866Phase 3Eli Lilly and CompanyA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing donanemab in Alzheimer Disease, from their registry updates:
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over videoconferencing
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants from the originating trials did not receive any drug in Part A. Participants were randomized 1:1 into two groups to have their cognitive and functional scales assessed. Group 1: Cognitive/functional scale assessment at the study site (on-site), followed by an at-home assessment (VTC; video teleconference), or Group 2: Cognitive/functional scale assessment at home (VTC), followed by assessment on-site. Total time in Part A was up to 24 weeks.
Other: No Intervention
Participants who had received placebo in the originating trials received 700 milligrams (mg) donanemab administered intravenously (IV) every 4 weeks (Q4W) for 3 doses, then 1400 mg donanemab administered IV Q4W for up to 48 weeks.
Drug: donanemab
No intervention
Administered IV
Also known as: LY3002813
Part A: Intraclass Correlation Between On-Site and Video Teleconference (VTC) Assessments
Part A didn't involve any drug and drug related efficacy analyses. Participants in Part A were divided into 2 groups, and they completed the same set of clinical assessments. Participants in Part A Group 1 completed the clinical assessments at a clinic site first (on-site) followed by at home assessments (VTC). Participants in Part A Group 2 completed the assessments at home first, followed by on-site assessment. The goal of Part A was to evaluate the comparability of remote and on-site clinical assessments. The intra-class correlation coefficient (ICC), a measure of agreement for continuous outcome measures, was used to determine agreement between remote and onsite assessments for each outcome measure. Outcome measure tested were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog13), Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL), Mini Mental State Examination (MMSE), and Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB).
Time frame: Baseline to 4 Weeks
Part B: Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Percentage of participants with TEAEs and SAEs were reported here. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.
Time frame: Baseline Up To 96 Weeks
Part B: Number of Participants With Suicidality Based on Columbia-Suicide Severity Rating Scale (C-SSRS)
Number of Participants with Suicidality Based on C-SSRS was reported.
Time frame: Baseline, Week 72
Part B: Change From Baseline on the Mini Mental State Examination (MMSE) Score
The MMSE is an instrument used to assess cognitive function in participants. The instrument measures orientation, memory, and attention; the ability of the participant to name objects; follow verbal and written commands; write a sentence; and copy figures. The range for the total MMSE score is 0 to 30, with lower scores indicating greater level of impairment. LS Mean was determined by Mixed Models for Repeated Measurements (MMRM) model with Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/ Absence of Anti-dementia Drugs as variables.
Time frame: Baseline, Week 72
Part B: Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) Score
The ADAS-Cog13 (13-item version of ADAS Cog) assesses areas of cognitive function that are the most typically impaired in Alzheimer's Disease (AD): orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze-completion measures. The ADAS-Cog13 scale ranges from 0 to 85, with higher scores indicating greater disease severity. LS Mean was determined by MMRM model with Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.
Time frame: Baseline, Week 72
Part B: Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)
The iADRS is a composite that measures both cognition and function from the ADAS-Cog and the ADCS-iADL (Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living). The iADRS is calculated as a linear combination of the total scores of the ADAS-Cog13 (score range 0 to 85 with higher scores reflecting worse performance) and the ADCS-iADL (score range from 0-59 with higher scores reflecting better performance). The iADRS score ranges from 0 to 144 with lower scores indicating greater impairment. LS Mean was determined by MMRM model using Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.
Time frame: Baseline, Week 72
Part B: Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL)
The ADCS-iADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean was determined by MMRM model using = Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.
Time frame: Baseline, Week 72
Part B: Change From Baseline on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
The CDR-SB is a global assessment tool than can be used to effectively evaluate both cognition and function. Participant's cognitive status is rated across 6 domains or 'boxes' of functioning: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. The CDR-SB scores are calculated by adding the box scores and range from 0 to 18 with higher scores indicative of more impairment. LS Mean was determined by MMRM model using Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.
Time frame: Baseline, Week 72
Part B: Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Florbetapir F18 Positron Emission Tomography (PET) Scan
Florbetapir PET imaging was used as a quantitative amyloid biomarker. Florbetapir PET scans at baseline and at 36 weeks after the first treatment were used to quantitatively estimate change in amyloid plaques. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. LS Mean was determined by ANCOVA model using originating study's Baseline + Age + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 36
Part B: Change From Baseline in Whole Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI)
Change from Baseline in Whole Brain Volume as Measured by vMRI in Part B. LS mean were derived using MMRM model with fixed factors for visit, and covariates for baseline score, and age at baseline.
Time frame: Baseline, Week 72
Part B: Pharmacokinetics (PK): Trough Concentrations of Donanemab (Ctrough)
PK: Trough Concentration of donanemab. Ctrough is the concentration of drug in the blood immediately before the next dose of drug was administered.
Time frame: Predose at Week 8 and Week 16
Part B: Number or Participants With Treatment-Emergent Anti-Drug Antibodies (TE ADA) of Donanemab
Number of participants in Part B with positive Anti-drug antibodies (TE ADA+) was reported. A TE ADA evaluable participant is classified as TE ADA+ if they have at least one postbaseline titer that is 4 times or more higher than the baseline titer (treatment-boosted). If the baseline result is ADA Not Present, the subject is considered TE ADA+ if there is at least one postbaseline result showing ADA present with a titer of 1:10 or higher (treatment-induced).
Time frame: Baseline, 4, 8, 16, 24, 36, 48, 60, 72, 84, and 96 Weeks
Study AACH was an extension of sponsor-approved originating donanemab studies AACC (NCT01837641) and AACG (NCT03367403). This was a two-part study (Parts A and B). Participants received the study drug only in Part B, whereas Part A consisted of clinical assessments.
| Milestone | Part A - Group 1: Validation of Remote Scale Assessments | Part A - Group 2: Validation of Remote Scale Assessments | Part B: Donanemab |
|---|---|---|---|
| Started | 50 | 45 | 0 |
| Received at least 1 dose of study drug | 0 | 0 | 0 |
| Completed | 43 | 39 | 0 |
| Not completed | 7 | 6 | 0 |
| Withdrew: Withdrawal by subject | 4 | 5 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Screen failure | 2 | 0 | 0 |
| Milestone | Part A - Group 1: Validation of Remote Scale Assessments | Part A - Group 2: Validation of Remote Scale Assessments | Part B: Donanemab |
|---|---|---|---|
| Started | 0 | 0 | 55 |
| Received at least 1 dose of study drug | 0 | 0 | 55 |
| Completed | 0 | 0 | 25 |
| Not completed | 0 | 0 | 30 |
| Withdrew: Withdrawal by subject | 0 | 0 | 18 |
| Withdrew: Adverse event | 0 | 0 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 2 |
| Withdrew: Progressive disease | 0 | 0 | 1 |
| Withdrew: Withdrawal due to caregiver circumstances | 0 | 0 | 1 |
Part A didn't involve any drug and drug related efficacy analyses. Participants in Part A were divided into 2 groups, and they completed the same set of clinical assessments. Participants in Part A Group 1 completed the clinical assessments at a clinic site first (on-site) followed by at home assessments (VTC). Participants in Part A Group 2 completed the assessments at home first, followed by on-site assessment. The goal of Part A was to evaluate the comparability of remote and on-site clinical assessments. The intra-class correlation coefficient (ICC), a measure of agreement for continuous outcome measures, was used to determine agreement between remote and onsite assessments for each outcome measure. Outcome measure tested were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog13), Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL), Mini Mental State Examination (MMSE), and Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB).
| Intraclass correlation coefficient | Part A: Validation of Remote Scale Assessments |
|---|---|
| ADAS-Cog13 | 0.8172 (0.7293 to 0.8785) |
| ADCS-ADL | 0.8819 (0.8227 to 0.9222) |
| MMSE | 0.8251 (0.7148 to 0.8907) |
| CDR-SB | 0.8254 (0.7380 to 0.8852) |
Percentage of participants with TEAEs and SAEs were reported here. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.
| Percentage of participants | Part B: Donanemab |
|---|---|
| TEAEs | 90.9 |
| SAEs | 29.1 |
Number of Participants with Suicidality Based on C-SSRS was reported.
| Participants | Part B: Donanemab |
|---|---|
| Suicidal Ideation | 3 |
| Suicidal Behavior | 1 |
The MMSE is an instrument used to assess cognitive function in participants. The instrument measures orientation, memory, and attention; the ability of the participant to name objects; follow verbal and written commands; write a sentence; and copy figures. The range for the total MMSE score is 0 to 30, with lower scores indicating greater level of impairment. LS Mean was determined by Mixed Models for Repeated Measurements (MMRM) model with Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/ Absence of Anti-dementia Drugs as variables.
| Score on a scale | Part B: Donanemab |
|---|---|
| Part B: Change From Baseline on the Mini Mental State Examination (MMSE) Score | -0.87 ± 0.557 |
The ADAS-Cog13 (13-item version of ADAS Cog) assesses areas of cognitive function that are the most typically impaired in Alzheimer's Disease (AD): orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze-completion measures. The ADAS-Cog13 scale ranges from 0 to 85, with higher scores indicating greater disease severity. LS Mean was determined by MMRM model with Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.
| Score on a scale | Part B: Donanemab |
|---|---|
| Part B: Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) Score | 4.63 ± 1.195 |
The iADRS is a composite that measures both cognition and function from the ADAS-Cog and the ADCS-iADL (Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living). The iADRS is calculated as a linear combination of the total scores of the ADAS-Cog13 (score range 0 to 85 with higher scores reflecting worse performance) and the ADCS-iADL (score range from 0-59 with higher scores reflecting better performance). The iADRS score ranges from 0 to 144 with lower scores indicating greater impairment. LS Mean was determined by MMRM model using Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.
| Score on a scale | Part B: Donanemab |
|---|---|
| Part B: Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) | -10.14 ± 1.850 |
The ADCS-iADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean was determined by MMRM model using = Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.
| Score on a scale | Part B: Donanemab |
|---|---|
| Part B: Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) | -6.21 ± 1.149 |
The CDR-SB is a global assessment tool than can be used to effectively evaluate both cognition and function. Participant's cognitive status is rated across 6 domains or 'boxes' of functioning: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. The CDR-SB scores are calculated by adding the box scores and range from 0 to 18 with higher scores indicative of more impairment. LS Mean was determined by MMRM model using Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.
| Score on a scale | Part B: Donanemab |
|---|---|
| Part B: Change From Baseline on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) | 1.87 ± 0.364 |
Florbetapir PET imaging was used as a quantitative amyloid biomarker. Florbetapir PET scans at baseline and at 36 weeks after the first treatment were used to quantitatively estimate change in amyloid plaques. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. LS Mean was determined by ANCOVA model using originating study's Baseline + Age + Treatment (Type III sum of squares) as variables.
| Centiloids | Part B: Donanemab |
|---|---|
| Part B: Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Florbetapir F18 Positron Emission Tomography (PET) Scan | -80.1 ± 4.40 |
Change from Baseline in Whole Brain Volume as Measured by vMRI in Part B. LS mean were derived using MMRM model with fixed factors for visit, and covariates for baseline score, and age at baseline.
| cubic centimeters (cm3) | Part B: Donanemab |
|---|---|
| Part B: Change From Baseline in Whole Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI) | -27.75 ± 2.060 |
PK: Trough Concentration of donanemab. Ctrough is the concentration of drug in the blood immediately before the next dose of drug was administered.
| micrograms per milliliter (μg/mL) | Part B: Donanemab |
|---|---|
| Ctrough at Week 8 | 5.62 ± 165 |
| Ctrough at Week 16 | 6.64 ± 581 |
Number of participants in Part B with positive Anti-drug antibodies (TE ADA+) was reported. A TE ADA evaluable participant is classified as TE ADA+ if they have at least one postbaseline titer that is 4 times or more higher than the baseline titer (treatment-boosted). If the baseline result is ADA Not Present, the subject is considered TE ADA+ if there is at least one postbaseline result showing ADA present with a titer of 1:10 or higher (treatment-induced).
| Participants | Part B: Donanemab |
|---|---|
| Part B: Number or Participants With Treatment-Emergent Anti-Drug Antibodies (TE ADA) of Donanemab | 38 |
Collected over Baseline Up To 96 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Part A - Group 1: Validation of Remote Scale Assessments | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| Period 1: Part A - Group 2: Validation of Remote Scale Assessments | 0/45 (0%) | 1/45 (2.2%) | 0/45 (0%) |
| Period 2: Part B: Donanemab | 2/55 (3.6%) | 16/55 (29.1%) | 40/55 (72.7%) |
| Event | Period 1: Part A - Group 1: Validation of Remote Scale Assessments | Period 1: Part A - Group 2: Validation of Remote Scale Assessments | Period 2: Part B: Donanemab |
|---|---|---|---|
| Amyloid related imaging abnormality-oedema/effusionNervous system disorders | 0/50 | 0/45 | 3/55 |
| Amyloid related imaging abnormality-microhaemorrhages and haemosiderin depositsNervous system disorders | 0/50 | 0/45 | 2/55 |
| SyncopeNervous system disorders | 0/50 | 1/45 | 1/55 |
| Acute myocardial infarctionCardiac disorders | 0/50 | 0/45 | 1/55 |
| Atrial fibrillationCardiac disorders | 0/50 | 0/45 | 1/55 |
| Cardiac failure congestiveCardiac disorders | 0/50 | 0/45 | 1/55 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/50 | 0/45 | 1/55 |
| FatigueGeneral disorders | 0/50 | 0/45 | 1/55 |
| CellulitisInfections and infestations | 0/50 | 0/45 | 1/55 |
| Covid-19Infections and infestations | 0/50 | 0/45 | 1/55 |
| Event | Period 1: Part A - Group 1: Validation of Remote Scale Assessments | Period 1: Part A - Group 2: Validation of Remote Scale Assessments | Period 2: Part B: Donanemab |
|---|---|---|---|
| Amyloid related imaging abnormality-oedema/effusionNervous system disorders | 0/50 | 0/45 | 15/55 |
| Amyloid related imaging abnormality-microhaemorrhages and haemosiderin depositsNervous system disorders | 0/50 | 0/45 | 10/55 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/50 | 0/45 | 8/55 |
| Covid-19Infections and infestations | 0/50 | 0/45 | 7/55 |
| FallInjury, poisoning and procedural complications | 0/50 | 0/45 | 7/55 |
| Urinary tract infectionInfections and infestations | 0/50 | 0/45 | 6/55 |
| HeadacheNervous system disorders | 0/50 | 0/45 | 4/55 |
| AstheniaGeneral disorders | 0/50 | 0/45 | 3/55 |
| Blood pressure increasedInvestigations | 0/50 | 0/45 | 3/55 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/50 | 0/45 | 3/55 |
All enrolled participants in Part A.
| Age, Continuous(years) | Part A: Validation of Remote Scale Assessments |
|---|---|
| Mean | 77.8 ± 5.6 |
| Sex: Female, Male(Participants) | Part A: Validation of Remote Scale Assessments |
|---|---|
| Female | 52 |
| Male | 43 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Validation of Remote Scale Assessments |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 83 |
| Unknown or Not Reported | 9 |
| Race (NIH/OMB)(Participants) | Part A: Validation of Remote Scale Assessments |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 93 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Part A: Validation of Remote Scale Assessments |
|---|---|
| Canada | 9 |
| United States | 86 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2020 to primary completion in Feb 2024, 39 months.
Results were first posted in Jun 2025, 1 year 3 months after primary completion.
Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 39 months is above that.
Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donanemab